{"id":"buprenorphine-transdermal-matrix-patch","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine's partial agonist activity at the mu-opioid receptor produces a ceiling effect on respiratory depression, making it safer than full opioid agonists. The transdermal matrix patch formulation provides sustained, controlled release of buprenorphine through the skin, enabling prolonged dosing intervals and improved patient compliance compared to oral or sublingual formulations.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce opioid cravings.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:56:57.943Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain management"},{"name":"Opioid use disorder maintenance treatment"}]},"trialDetails":[{"nctId":"NCT06442566","phase":"PHASE1, PHASE2","title":"ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2024-08-12","conditions":"Opioid Withdrawal, Chronic Pain","enrollment":240},{"nctId":"NCT05790252","phase":"PHASE3","title":"Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-11-27","conditions":"Opioid Use Disorder, Pregnancy Related, Pregnancy, High Risk","enrollment":40},{"nctId":"NCT06949826","phase":"PHASE4","title":"Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery","status":"RECRUITING","sponsor":"Jenna-Leigh Wilson","startDate":"2025-04-21","conditions":"Pain, Postoperative, Ankle Fracture Surgery, Opioid Use Disorder","enrollment":100},{"nctId":"NCT04752384","phase":"PHASE2","title":"Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2021-07-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT05871424","phase":"NA","title":"Transdermal Buprenorphine Patch for Laparoscopic Cholecystectomy","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2023-06-11","conditions":"Laparoscopic Cholecystectomy","enrollment":66},{"nctId":"NCT03977012","phase":"","title":"Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome Patients","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2019-06-11","conditions":"Complex Regional Pain Syndromes","enrollment":20},{"nctId":"NCT05042648","phase":"PHASE4","title":"Role of Preoperative Transdermal Buprenorphine Patch in Reducing Postoperative Opioids Consumption in Patients Undergoing Total Knee Arthroplasties - A Randomised Controlled Trial.","status":"UNKNOWN","sponsor":"Security Forces Hospital","startDate":"2021-12-01","conditions":"Patients Aged Between 18 and 65years Undergoing Total Knee Arthroplasty","enrollment":120},{"nctId":"NCT04315831","phase":"","title":"Safety and Effectiveness of Transdermal Buprenorphine in Cancer Pain","status":"COMPLETED","sponsor":"Taiwan Mundipharma Pharmaceuticals Ltd.","startDate":"2018-01-31","conditions":"Cancer","enrollment":83},{"nctId":"NCT00916890","phase":"PHASE4","title":"Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain","status":"SUSPENDED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2009-02","conditions":"Chronic Pain","enrollment":320},{"nctId":"NCT00886002","phase":"PHASE1","title":"Comparison of Two Dosage Strengths of Transdermal Fentanyl Versus Transdermal Buprenorphine and Placebo in Acute Pain Models in Healthy Volunteers.","status":"COMPLETED","sponsor":"Janssen-Cilag A.G., Switzerland","startDate":"2004-11","conditions":"Pain","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Buprenorphine Transdermal Matrix Patch","genericName":"Buprenorphine Transdermal Matrix Patch","companyName":"Washington University School of Medicine","companyId":"washington-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to opioid receptors in the central nervous system to provide analgesia and reduce opioid cravings. Used for Chronic pain management, Opioid use disorder maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}